Fecal Microbiota Transplantation (FMT) is suggested as an efficacious therapeutic strategy for restoring intestinal microbial balance, and thus for treating disease associated with alteration of gut microbiota. FMT consists of the administration of fresh or frozen fecal microorganisms from a healthy donor into the intestinal tract of diseased patients. At this time, in according to healthcare authorities, FMT is mainly used to treat recurrent Clostridium difficile. Despite the existence of a few existing stool banks worldwide and many studies of the FMT, there is no standard method for producing material for FMT, and there are a multitude of factors that can vary between the institutions. The main constraints for the therapeutic uses of FMT are safety concerns and acceptability. Technical and logistical issues arise when establishing such a non-standardized treatment into clinical practice with safety and proper governance. In this context, our manuscript describes a process of donor safety screening for FMT compiling clinical and biological examinations, questionnaires and interviews of donors. The potential risk of transmission of SARS-CoV-2 virus by the use of fecal microbiota for transplantation must be taken urgently into consideration. We discuss a standardized procedure of collection, preparation and cryopreservation of fecal samples through to the administration of material to patients, and explore the risks and limits of this method of FMT. The future success of medicine employing microbiota transplantation will be tightly related to its modulation and manipulation to combat dysbiosis. To achieve this goal, standard and strict methods need to be established before performing any type of FMT.This procedure could be also indicated to treat other diseases associated with alteration of gut microbiota [5].The use of FMT was proposed from the 4th century AD and has been widely studied and documented since 2013, when the U.S. Food and Drug Administration approved FMT for the treatment of recurrent and refractory Clostridium difficile infections. In the 4th century yellow soup, as it was called in China, represented the feces used in patients with severe diarrhea. Accounts of treatment with fresh or fermented fecal suspensions applied in patients with gastrointestinal disorders, including diarrhea, constipation, and abdominal pain were described until the Chinese Ming Dynasty in the 16th century [6,7]. More recently, Eiseman and his colleagues successfully treated patients with FMT for Pseudomembranous colitis, in 1958, the first report in the medical literature [8]. With the increasing numbers of trials and the sharing of results around the world, mixed results have been observed, suggesting that heterogeneity in donor stool may play a role in patient response. Studies hypothesize that the microbiome is associated with a given indication [6][7][8]. Thus, fecal material collections should be informed by the health of the donors but also categorized to associate the donor with a recipient as part of a selection s...